VRPX Stock Overview
A preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Virpax Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$84.75 |
| 52 Week Low | US$0.13 |
| Beta | 1.53 |
| 1 Month Change | -11.47% |
| 3 Month Change | -96.62% |
| 1 Year Change | -98.77% |
| 3 Year Change | -99.94% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| VRPX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.3% | 0.2% | -1.4% |
| 1Y | -98.8% | -12.1% | 10.5% |
Return vs Industry: VRPX underperformed the US Pharmaceuticals industry which returned -12.4% over the past year.
Return vs Market: VRPX underperformed the US Market which returned 9.1% over the past year.
Price Volatility
| VRPX volatility | |
|---|---|
| VRPX Average Weekly Movement | 27.0% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VRPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRPX's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 2 | Jay Dhaliwal | www.virpaxpharma.com |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. Fundamentals Summary
| VRPX fundamental statistics | |
|---|---|
| Market cap | US$267.14k |
| Earnings (TTM) | -US$12.07m |
| Revenue (TTM) | n/a |
Is VRPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRPX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.07m |
| Earnings | -US$12.07m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VRPX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 06:11 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virpax Pharmaceuticals, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |
| Ashok Kumar | ThinkEquity LLC |